Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.

Vitamin D reduces anti-dsDNA positivity in systemic lupus erythematosus

25 Jul 2017
Vitamin D supplementation decreases positivity to anti-double stranded (ds) DNA in systemic lupus erythematosus (SLE), according to a new meta-analysis.

A meta-analysis of three studies (intervention group, n=233; placebo, n=128) that evaluated the positivity to anti-dsDNA in SLE showed that vitamin D supplementation resulted in a significant drop in anti-dsDNA positivity (risk difference, -0.10; 95 percent CI, -0.18 to -0.03; p=0.005).

After 6 months of vitamin D supplementation, the following fatigue measurements in SLE showed significant improvements: fatigue interfering with social life (p=0.01), fatigue considered a problem (p=0.03), fatigue from medium effort (p=0.02), fatigue easily (p=0.003) and fatigue when performing exercise (p=0.03).

On the other hand, in rheumatoid arthritis (RA), vitamin D did not have significant effects on the visual analogue scale (VAS; mean difference, 2.79; -1.87 to 7.44; p=0.24) or on the disease activity score 28 (DAS-28; mean difference, -0.31; -0.86 to 0.25; p=0.28), according to an analysis of two studies (intervention, n=61; placebo, n=59).

Two other studies (intervention, n=124; placebo, n=128) showed that RA recurrence decreased although insignificantly (mean difference, -0.10; -0.21 to 0.00; p=0.05).

The meta-analysis included seven randomized controlled trials that investigated the effects of vitamin D supplementation on adult participants with immune-mediated rheumatic diseases. Those with exclusively bone metabolism or cardiovascular endpoints were excluded.

The databases of Medline, Embase, Lilacs, CINAHL and Cochrane were accessed for this meta-analysis.

Quality of the studies was measured from the following criteria: query of the study, randomization, blinding, concealment, participant attrition, homogeneity, outcome measures and intention-to-treat analysis. All studies had a high risk of bias for at least one of the aforementioned criteria.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.